MCL1 and breast cancer: These findings are consistent with previous reports describing increased translation of Mcl-1 in Bcl-xL-impaired breast cancer cells harboring PIK3CA activating mutations (17), a mutation that increases signaling through phosphatidyl inositol-3 kinase (PI3K) and its downstream effector mTOR.